Quick Answer
Quince Therapeutics, Inc. reported Cash and Equivalents of $51.21 million for fiscal year 2019.
Quince Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2019 | $51.21M | +105.9% |
| 2018 | $24.87M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.45M | — | -61.7% |
| June 30, 2025 | $16.83M | — | +116.5% |
| March 31, 2025 | $7.77M | — | +25.1% |
| December 31, 2024 | $6.21M | — | -90.3% |
| September 30, 2020 | $64.25M | +43.6% | -2.9% |
| June 30, 2020 | $66.16M | +49.3% | -22.7% |
| March 31, 2020 | $85.61M | +314.9% | +67.2% |
| December 31, 2019 | $51.21M | +105.9% | +14.5% |
- Quince Therapeutics, Inc. showed an increase of +105.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2019 period, Quince Therapeutics, Inc.’s cash and equivalents has grown by 105.9% (from $24.87 million to $51.21 million).
- The most recent figure is from Quince Therapeutics, Inc.’s fiscal year 2019 report (Form 10-K), filed with the SEC on March 16, 2020.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: